We gebruiken cookies om ervoor te zorgen dat onze site zo soepel mogelijk draait. Als je doorgaat met het gebruiken van deze site, gaan we er vanuit dat je ermee instemt.
Daratumumab is een middel dat zich richt op het eiwit CD38, vooral sterk aanwezig in myeloom cellen. Door zich te binden aan het eiwit zorgt daratumumab ervoor dat het eigen immuunsysteem wordt geactiveerd en het multipel myeloom beter kan worden bestreden. In dit onderzoek werd gekeken wat het effect is van daratumumab in combinatie met […]
Er zijn verschillende risicofactoren voor hart- en vaatziekten zoals geslacht, leeftijd, roken, diabetes, hypertensie en obesitas, maar dyslipidemie i...
Hedendaagse chemotherapie voor acute lymfoblastische leukemie (ALL) bij kinderen wordt aangepast aan het risico op basis van klinische kenmerken, gene...
Plerixafor is an adjunct peripheral blood stem cell (PBSC) mobilization agent with well-demonstrated safety and efficacy. The routine use of the origi...
Hepatitis B core antibody (anti-HBc) screening has been implemented in many blood establishments to help prevent transmission of hepatitis B virus (HB...
Blood services must consider innovative ways to encourage more Black people to donate to enhance the efficacy of treatments. We evaluate how two innov...
Pediatric patients from minoritized racial and ethnic groups receive red blood cell (RBC) transfusions more frequently while undergoing major surgical...
Platelet-rich microvascular thrombi are common in severe COVID-19. Endogenous nitric oxide (NO)-signaling limits thrombus formation and previously we identified platelet subpopulations with a differential ability to produce NO based on the presence or absence of endothelial nitric oxide synthase (eNOS). eNOS expression is counter-regulated by cytokines, and COVID-19-associated immune/inflammatory responses may affect the transcriptome profile of megakaryocytes and their platelet progeny.
Belief BioMed (BBM), an innovative Chinese biotechnology company focused on developing cutting─edge gene therapies, announced that the Medical Products Administration (NMPA) of China has accepted the company's new drug application (NDA) for BBM─H901 for treatment of adults with haemophilia B.
Heparin-induced thrombocytopenia (HIT) is a rare complication of heparin exposure with potential for significant morbidity and mortality. Early identification and treatment can prevent catastrophic thrombosis. Herein, we report the performance of a platelet count-based clinical decision support system (CDSS) where providers received a notification when a patient had a platelet count decline of ?50?%. In the 90-day study period, the CDSS sent 302 notifications on 270 patients. Notifications were frequently inappropriate; 25?% had an expected platelet count decline (organ donation, stem cell transplant), an inaccurate count, or no heparin exposure.
Onderwerpen
Blogs
7 augustus 2023
Volg
